EMA Authorised: INOmax (nitric oxide) — Linde Healthcare AB

View source ↗

Summary

The EMA authorized INOmax (nitric oxide) for pulmonary hypertension and respiratory insufficiency. The marketing authorization holder is Linde Healthcare AB, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Respiratory Insufficiency

Drugs mentioned

• INOmax (nitric oxide)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary;Respiratory Insufficiency. MAH: Linde Healthcare AB. Decision date: 15/05/2025